Deadline- September 20, 2012
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seeking propsals for Accelerating DRUG DISCOVERY for Frontotemporal Dementias .
Priority areas for this program include–
- Target validation studies
- Development and testing of novel high throughput screening assays
- Medicinal chemistry on lead compounds
- Identification and in vitro testing of potentially disease modifying lead compounds
- ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds
- Testing of lead compounds in a relevant animal model for preclinical proof of concept
- Development of biomarkers to accelerate drug development and early diagnosis
- Innovative pilot clinical trials
ADDF/AFTD will provide grants for one-year duration (up to $150,000 each) with the possibility of follow-on funding. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program-related investment.
For more information, visit this link
